BioSpace News Archive

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the presentation of a poster at the Antibody Engineering & Therapeutics Europe Virtual conference which was held June 8 – 10, 2021

AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors (the “Buyers”),

Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced positive topline results for the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D)

Cullgen Inc., today announced that Mark Deeg, M.D., Ph.D., has joined the company as Executive Vice President of Clinical Development.

The DNA Data Storage Alliance, an organization of more than 25 leading companies formed by Twist Bioscience Corporation, Illumina, Inc. and Western Digital together with Microsoft Research, announced its first white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.”.

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has closed an oversubscribed $107.5 million Series B financing.

Forge Biologics announced today that it will be delivering a company presentation at BIO Digital, hosted by the Biotechnology Innovation Organization, being held June 10-11 and 14-18, 2021.

CURE Pharmaceutical Holding Corp. announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.

CBMG Holdings (or the “Company”), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated clinical data for C-CAR039, a novel CD19/CD20 bi-specific CAR-T cell product in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL)

Medexus Pharmaceuticals Inc. announced that it has expanded its medical affairs team in preparation for the planned launch of treosulfan, a bifunctional alkylating agent, in the United States.